The world’s largest clinical trial for multidrug-resistant tuberculosis (MDR-TB) has found that the two new shortened treatment regimens are safe and effective. The newly published trial result also indicates lower patient direct costs. The long-awaited results from stage 2 of…
The rollout of a drug resistant tuberculosis (TB) regimen that is shorter and has reduced side effects is expected in 2023. In May, the World Health Organisation (WHO) approved a new six-month regimen, that slashed treatment time by a third.…
South African children will have to wait until next year for the rollout of the child friendly, ‘sweet-tasting’ antiretroviral (ARV) treatment, despite this new 4-in-1 combination receiving the green light. The South African Health Products Regulatory Authority (SAHPRA) approved the…
Despite studies proving that the new HIV treatment drug – dolutegravir (DTG) – is highly effective at suppressing the virus in the body with fewer side effects, millions of South Africans remain on the old efavirenz regimen. In 2019, the…